Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460

Cancer Research

Volumn 60, Issue 24, 2000, Pages 7133-7141

  Ferreira, C G ^a   Span, S W ^a   Peters, G J ^a   Kruyt, F A E ^a   Giaccone, G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CISPLATIN; ENZYME PRECURSOR; FAS ANTIGEN; GEMCITABINE; PROTEIN BCL 2; PROTEIN BCL X; TOPOTECAN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHEMOTHERAPY; CLONOGENESIS; CONTROLLED STUDY; CYTOKINE RESPONSIVE ELEMENT; ENZYME ACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LUNG NON SMALL CELL CANCER; MITOCHONDRION; PRIORITY JOURNAL; SOLID TUMOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID CHLOROMETHYL KETONES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CASPASE 8; CASPASE 9; CASPASES; CISPLATIN; CYTOCHROME C GROUP; CYTOSOL; DEOXYCYTIDINE; DNA, COMPLEMENTARY; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GENES, DOMINANT; HUMANS; INHIBITORY CONCENTRATION 50; JURKAT CELLS; LUNG NEOPLASMS; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; SPECTROMETRY, FLUORESCENCE; TOPOTECAN; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034671206     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. An update on North American randomized studies in non-small cell lung cancer
2. Apoptosis in cancer therapy: Crossing the threshold
3. Human ICE/CED-3 protease nomenclature
4. Caspases: The executioners of apoptosis
5. Caspases: Enemies within
6. Caspases: The proteases of the apoptotic pathway
7. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis
8. Biochemical pathways of caspase activation during apoptosis
9. Differential requirement for caspase 9 in apoptotic pathways in vivo
10. Release of mitochondrial cytochrome c is upstream of caspase activation in chemical-induced apoptosis in human monocytic tumour cells
11. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-I-and TNF receptor-induced cell death
12. FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens
13. Two CD95 (APO-1/Fas) signaling pathways
14. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
15. An APAF-1. Cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9
16. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization
17. The proto-oncogene Bcl-2 and its role in regulating apoptosis
18. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma
19. L is expressed in neuroblastoma cells and modulates chemotherapy- induced apoptosis
20. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD- specific caspase activation and independently of mitochondrial transmembrane depolarization
21. Mitochondrial control of nuclear apoptosis
22. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis
23. Target protease specificity of the viral serpin CrmA. Analysis of five caspases
24. Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35
25. X-linked IAP is a direct inhibitor of cell-death proteases
26. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases
27. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
28. Cleavage of human inhibitor of apoptosis protein X1AP results in fragments with distinct specificities for caspases
29. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner
30. Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and γ-radiation downstream from caspase- 8 activation
31. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells
32. Inhibition of apoptosis and clonogenic survival of cells expressing crmA variants: Optimal caspase substrates are not necessarily optimal inhibitors
33. L and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death
34. A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis
35. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95
36. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis
37. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway
38. Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway
39. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry
40. In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil
41. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines
42. Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells
43. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes
44. Inhibition of human caspases by peptide-based and macromolecular inhibitors
45. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction
46. Dominant-negative FADD inhibits TNFR60-, Fas/Apol-, and TRAIL-R/Apo2- mediated cell death but not gene induction
47. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis
48. Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents
49. Processing/activation of caspases, -3 and -7 and -8 but not caspase-2, in the induction of apoptosis in B-chronic lymphocytic leukemia cells
50. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells
51. Thymineless death in colon carcinoma cells is mediated via fas signaling
52. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
53. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions
54. Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95- and anticancer drug-induced apoptosis
55. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells
56. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid
57. L interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation
58. Molecular ordering of the Fas-apoptotic pathway: The Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases
59. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
60. Cell-cycle arrest versus cell death in cancer therapy
61. p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat- 1 fibroblasts constitutively expressing c-Myc
62. An information-intensive approach to the molecular pharmacology of cancer
63. Recessive mutations in a common pathway block thymocyte apoptosis induced by multiple signals